MGX · Metagenomi Therapeutics Inc
United States · RS rating 11 · As of 2026-11-03
| Price | 0.76 USD |
|---|---|
| 1-day change | +0.7% |
| RS rating (overall / 1M / 3M / 12M) | 11 / 15 / 15 / 12 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 16 / 4 / 18 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -19.7% |
| Sales growth Q/Q | -54.8% |
| Distance from 52-week high | +68.6% |
| Market cap (USD) | $53.8M |